Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Amicus Therapeutics
Amicus Therapeutics
Activities:
Research & Development
Finance
Pharmaceutical
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Manufacturing
Catalent wins CDMO contract with Amicus Therapeutics
The US biotech company has chosen Paragon Gene Therapy development and manufacturing capability for lysosomal disorder programmes
Manufacturing
Amicus chooses Thermo Fisher for gene therapy CDMO services
Collaboration will focus on the rare genetic cause of Batten disease
Design & Build
Amicus builds global R&D centre for gene therapy in the US
Located in Philadelphia, the new 75,000 sqft facility will be completed in the second half of 2019
Manufacturing
WuXi Biologics inks commercial agreement with Amicus
Chinese biotech company has become exclusive drug substance manufacturing partner and key commercial drug product supplier for Pompe biologic ATB200
Research & Development
Drug licensing deals in 2010
Big pharma companies have been busy filling the yawning gaps in their product pipelines by licensing drugs developed by smaller biotechnology firms. Dr Sarah Houlton outlines a selection of the deals done this year
Research & Development
GSK and Amicus Therapeutics sign exclusive agreement
To develop and commercialise Amigal for Fabry disease
Subscribe now